<DOC>
	<DOCNO>NCT02819687</DOCNO>
	<brief_summary>A Phase I , single-center , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics single-and multiple-ascending dos RDX5791 healthy male female subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics RDX5791 Healthy Volunteers</brief_title>
	<detailed_description>In single-ascending dose ( SAD ) , 5 separate cohort receive RDX5791 various dos po fast . Each cohort 8 subject ( 6 RDX5791 , 2 placebo ) receive diet standardized fro Na+ content wile clinical pharmacology unit ( CPU ) . The PK data 50-mg dose safety data 150-mg dose SAD study evaluate prior proceed multiple-ascending dose ( MAD ) phase . Doses RDX5791 3 , 10 , 30 , 100 mg administer daily po fasting . Four cohort 10 subject ( 8 RDX5791 , 2 placebo ) receive diet standardized Na+ content CPU . Safety assessment include clinical assessment vital sign , clinical laboratory evaluation , ECGs , AE monitoring perform regular interval . Plasma collect regular interval PK analysis . The PD assessment include stool frequency consistency , well change urinary Na+ excretion . All bowel movement collect analyzed Na+ content outside study protocol .</detailed_description>
	<criteria>BMI 18 29.9 kg/m² , inclusive Females must nonchildbearing potential ; If childbearing potential , must negative pregnancy test confirm use one appropriate mean contraception Males must agree use appropriate method barrier contraception document surgical sterilization Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract Any surgery small intestine colon , exclude appendectomy Loose stool ( Bristol Stool Form Score 6 7 ) ≥2 day past 7 day Hepatic dysfunction ( [ ALT ] [ AST ] ) &gt; 1.5 time upper limit normal renal impairment Any evidence treatment malignancy , exclude nonmelanomatous malignancy skin Use diuretic medication , medication know affect stool consistency and/or GI motility Use investigational agent within 30 day prior Day 2 Positive virology , alcohol , drug abuse test screening Use prescription medication within 7 day admission CPU Have significant blood loss ( &gt; 450 mL ) donate 1 unit blood plasma within 8 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>